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The budding yeast Saccharomyces cerevisiae is a valuable system to study cell-cycle regulation, which is defective in cancer cells.
Due to the highly conserved nature of the cell-cycle machinery between yeast and humans, yeast studies are directly relevant to
anticancer-drugdiscovery.Thebuddingyeastisalsoanexcellent modelsystemforidentifyingandstudyingantifungalcompounds
because of the functional conservation of fungal genes. Moreover, yeast studies have also contributed greatly to our understanding
ofthebiologicaltargetsandmodesofactionofbioactivecompounds.Understandingthemechanismofactionofclinicallyrelevant
compounds is essential for the design of improved second-generation molecules. Here we describe our methodology for screening
a library of plant-derived natural products in yeast in order to identify and characterize new compounds with anti-proliferative
properties.
1.Introduction
Despite an increasing awareness and expenditure of
resources, the incidence of cancer has not declined in
decades, and, in fact, is rising in some areas at an alarming
rate. Despite enormous outlays of research dollars, the
number of novel cancer drugs has remained ﬂat over the past
two decades. Screening natural products for potential new
drugsrepresentsthebestavenuetodiscovernew,inexpensive
and eﬀective drugs to treat cancer [1, 2].
Morocco is very rich in medicinal plants widely used in
folk medicine to prevent or cure many diseases. Morocco’s
unique geography comprises all bioclimatic stages in the
Mediterranean zone, with an extraordinarily abundant and
diverse vegetation represented by ∼42000 plant species.
Estimates of the number of medicinal plants used by
Moroccan healers suggest that several hundreds of species
containing several thousand bio-active compounds could be
useful in treating human disease [3–8]. However, it is often
diﬃcult to identify these bioactive natural compounds and
to study their eﬀect at the cellular level or their mechanism
of action. Therefore, understanding the role of these natural
compounds requires the development of high resolution yet
cost-eﬀective biological assay systems.
The budding yeast Saccharomyces cerevisiae is an excel-
lent model system for identifying and studying antifungal
compounds because of the functional conservation of fungal
genes. Therefore, to accelerate the discovery of bioactive
compounds with antifungal activity, Gassner et al. [9]h a v e
developed an automated yeast toxicity screen which they
call high-throughput (HT) yeast halo assay. Yeast studies
have also contributed greatly to our understanding of the
biological targets and modes of action of bioactive com-
pounds [10–14]. Understanding the mechanism-of-action
of clinically relevant compounds is essential for the design
ofimproved second-generationmolecules.Yeast-basedfunc-
tional genomics technologies are excellent means for mech-
anistic studies of clinically relevant compounds. Due to the2 Evidence-Based Complementary and Alternative Medicine
highly conserved nature of the cell-cycle machinery between
yeast and humans, the budding yeast is also an excellent
model system to study cell-cycle regulation [15–17], which is
defective in cancer cells. Therefore, yeast studies are directly
relevanttoanticancer-drugdiscovery[10,18].Hereweshow,
through an example, our procedure for the identiﬁcation
and characterization of new plant-derived natural products
with anti-proliferative properties using the budding yeast as
a drug discovery tool.
2. Selection of Growth-InhibitoryCompounds
In order to identify new molecules of potential therapeutic
interest, we ﬁrst constructed a library of chemical molecules
provided by phytochemists. We next assessed the growth-
inhibition eﬀects of these molecules in yeast to identify
compounds with antifungal activity. Thus, from 40 plant
extracts and 14 puriﬁed plant-derived natural molecules
analyzed, we identiﬁed 14 plant extracts and 8 natural
molecules that have clear growth-inhibitory eﬀects. We show
here the characterization of Lyc, a plant-derived natural
alkaloid product. To assess the eﬀect of Lyc on yeast growth,
yeast cells in logarithmic phase were incubated with or
without Lyc. As shown in Figure 1, addition of Lyc resulted
inasigniﬁcantlyreducedgrowthrateofyeastcells,indicating
that Lyc exhibited bioactivity in yeast, resulting in inhibition
of growth. Using this screen we selected a number of growth-
inhibitory compounds that were further characterized in
order to understand their mode of action.
3. Mechanismof Action
3.1. Cell-Cycle Analysis. Cell-cycle analysis was ﬁrst under-
taken to determine whether a compound causes cell-cycle
perturbation. In S. cerevisiae, it is easy to monitor cell-cycle
progression by measuring DNA content using Fluorescence-
Activated Cell Sorting (FACS) [18]. For example, abnormal
accumulation of cells with 1C DNA content of an expo-
nentially growing culture usually indicates a defect in the
G1 phase of the cell cycle. Thus, to further investigate the
growthdefectcausedbyLyctreatment,cell-cycleprogression
was assessed using FACS analysis. Logarithmically growing
cultures were incubated in the presence or absence of Lyc. At
theindicatedtimessampleswereﬁxedandtheDNAcontents
of cells in each sample were measured by ﬂow cytometry
(Figure 2). In comparison with the no drug control culture,
an increase in the number of cells with a 1C (or G1) DNA
content was observed, starting at 2h and persisting for the
duration of the experiment. After 4 and 8 h of Lyc treatment,
accumulation of cells with abnormal DNA contents (neither
1C nor 2C) was evident. Thus, these results suggest that Lyc
perturb cells-cycle progression.
3.2. Phenotypic Analysis. Saccharomyces cerevisiae divides by
budding and shows speciﬁc cell morphologies at diﬀerent
stages of the cell cycle. Unbudded cells are in the G1
phase, small budded cells are in the S phase, and large
budded cells are in the G2/M phase of the cell cycle
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Figure 1: Growth of wild-type (OD 600nm) as a function of
time. Wild-type cells were diluted from an overnight culture to an
OD600 of ∼0.01 and allowed to grow until the OD600 reached
∼0.05, ensuring that the cells were in logarithmic phase. Drug was
then added and growth rate was measured as the optical density
of cells (OD600) as a function of time (h) in rich medium. All
compounds were diluted in 100% DMSO, and all assays, including
the “no compound” control, contained 1% DMSO. The growth in
the presence of 100μg/ml of natural compound Lyc is presented.
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Figure 2: Cell-cycle analysis. In the presence of Lyc, cells show
aberrant DNA content. Cells treated with Lyc display cell-cycle
perturbation. Wild-type strain was incubated in the presence or
absence of Lyc. Samples at the indicated time points were analyzed
by ﬂow cytometry to measure DNA content (1C and 2C peaks are
indicated).
(Figure 3(a)). Thus, it is easy to monitor cell-cycle pro-
gression by simply observing cells using ﬂuorescence and
diﬀerential interference contrast microscopy. Therefore, to
further investigate the eﬀect of Lyc on cell-cycle progression,
yeast cells in logarithmic phase were incubated with or
without Lyc and then visualized by diﬀerential interference
contrast (DIC) microscopy. We discovered that cells treated
with Lyc exhibit a characteristic morphological alteration,
with most cells either unbudded or abnormal with multiple
buds (Figure 3(a)). Additionally, DAPI staining of cellularEvidence-Based Complementary and Alternative Medicine 3
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Figure 3: Phenotypic analysis. (a) Representative images of asynchronously growing wild-type cells in the absence or presence of Lyc for 8h.
Cells treated with Lyc exhibit strong morphological alteration and fragmented nuclei. For each ﬁeld of cells, diﬀerential interference contrast
(left) and DAPI staining of DNA (right) images were taken. Speciﬁc cell morphologies at diﬀe r e n ts t a g e so ft h ec e l lc y c l ea r es h o w nf o rt h e
no drug control. (b) FACS proﬁle of cells from the experiment in (a). (c) Budding index was measured for growing wild-type cells from the
experiment in (a). Cells were counted in each of two experiments, and the average of the two experiments is showed.
DNA revealed that treated cells typically had a fragmented
nucleus (Figure 3(a)). Most cells had two or more DAPI-
staining nuclear fragments, indicating that Lyc disrupts the
integrity of the nucleus, consistent with the accumulation
of cells with abnormal DNA contents observed by FACS
analysis of the same cell sample (Figure 3(b)). Furthermore,
we scored the proportion of unbudded (G1), small budded
(S), large budded (G2/M) and abnormal cells in the presence
orabsenceofLyc.AsshowninFigure 3(c)andincomparison
with the no drug control, most cells treated with Lyc were
abnormal (41% large unbudded and 22% multi-budded
cells) and only few cells were in S or G2/M phases of the
cellcycle.Together,thesedatasuggestthattreatmentwithLyc
impairs normal cell-cycle progression, perhaps as a result of
nuclear fragmentation. However, for more detailed analysis
of the eﬀect of Lyc on cell-cycle progression, cells should be
arrested in speciﬁc stages of the cell cycle and then released
synchronously into the cell cycle [19–21]. To detect G1 or
S phase progression defects, cells can be arrested in G1
with the mating pheromone alpha factor, then released into
media with or without Lyc. In contrast, mitotic defects can
be detected following arrest in G2 using the microtubule
inhibitor nocodazole, then released into media with or
without Lyc.
3.3. Chemical-Genetic Proﬁling. Yeast-based functional ge-
nomics technologies are excellent means for mechanistic
studies of compounds with antifungal activity. In particular,
chemical-genetic proﬁling has been used to study the mode
of action of a number of growth-inhibitory com-pounds.
Recently, in a proof-of-concept manuscript, we demon-
strated that chemical-genetic proﬁling in yeast contributes
greatly to understand the modes of action of bioactive com-
pounds in human cells [10]. Brieﬂy, in these assays, a pooled4 Evidence-Based Complementary and Alternative Medicine
collection of homozygous (or MATα haploid) viable dele-
tion mutants, each in a diﬀerent gene, is ﬁrst grown in the
presence or absence of a growth-inhibitory compound.
Then, following growth, deletion strains that are under-re-
presented, and therefore sensitive, in the presence of
compound relative to the control condition are identiﬁed
by hybridizing the unique DNA sequences which ﬂank
each deletion to their complements on a DNA microarray
[10–14]. This system identiﬁes a set of deletion mutant
strainshypersensitivetoagivencompound,referredtoasthe
chemical-geneticproﬁle.Theresultsofthesestudiestypically
determine which pathways are important for drug resistance
and therefore give insights into compound mode-of-action.
Inordertoidentifythedrugtargetchemical-geneticproﬁling
is carried out using a complete collection of heterozygous
deletion strains. In this second type of proﬁling, referred to
as HaploInsuﬃciency Proﬁling (HIP), a pooled collection of
all ∼6000 heterozygous deletion mutants, each in a diﬀerent
gene, can be grown in the presence or absence of a drug.
Then, strain ﬁtness can be determined by DNA microarray
analysis of the PCR-ampliﬁed barcodes incorporated into
eachstrain.Heterozygousstrainsmostsensitivetodrugcarry
deletions in genes which encode the likely drug targets [11].
Therefore, in order to determine the mode of action of
Lycchemical-geneticproﬁlingwasperformedusingthecom-
plete pool of barcoded MATα haploid viable deletion strains.
Preliminary data show that the most sensitive mutants to
Lyc are involved in translation regulation, suggesting that
this compound may aﬀect protein biosynthesis. Further
investigation is required to conﬁrm this result and to
determine the precise target of Lyc.
4. Conclusion
The budding yeast S. cerevisiae is an excellent model system
for identifying plant-derived natural products with anti-
proliferative properties. As proof of principle, we showed
that yeast cells treated with Lyc exhibited cell-cycle pertur-
bation, fragmented nuclei, and morphological alterations.
Compounds with these properties are excellent candidates
for further study, as they might target components of the
cell-cycle regulation machinery, and so could have anti-
proliferative properties of therapeutic value. Such com-
pounds could be useful in treating proliferative diseases such
as cancers, or in treating fungal infections.
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